TrianglePirtobrutinib (NCT07231952)
Pirtobrutinib trial for Waldenstrom Macroglobulinemia (NCT07231952). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with previously untreated Waldenström's macroglobulinemia or IgM-producing lymphoplasmacytic lymphoma that needs treatment. Non-IgM disease is excluded.
The idea: combine daily pirtobrutinib and venetoclax tablets with rituximab, given by infusion or injection under the skin. Pirtobrutinib blocks BTK growth signaling; venetoclax blocks BCL-2, a protein that helps cancer cells survive; rituximab targets CD20 to trigger an immune attack. Researchers measure deep responses with this planned, time-limited treatment.
This phase 2 study plans 40 patients. Lia Palomba leads at Memorial Sloan Kettering; nine US locations are listed as recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.